Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs

Drugs

Volumn 53, Issue 4, 1997, Pages 563-582

  Jouzeau, Jean Yves ^a   Terlain, Bernard ^a   Abid, Amr ^a   Nédélec, Emmanuelle ^a   Netter, Patrick ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 5 BROMO 2 (4 FLUOROPHENYL) 3 (4 METHYLSULFONYLPHENYL)THIOPHENE; 6 (2,4 DIFLUOROPHENYLTHIO) 5 METHANESULFONAMIDO 1 INDANONE; ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLOSULIDE; IGURATIMOD; INDOMETACIN; ISOENZYME; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME REGULATION; ENZYME STRUCTURE; GASTROINTESTINAL TOXICITY; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; REVIEW; STOMACH DISEASE;

EID: 0030911815     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199753040-00003     Document Type: Review

References (238)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232-5
2. Smith WL, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature New Biol 1971; 231: 235-7
3. Ferreira SH, Moncada S, Vane JR. Indomethacin and aspirin abolish prostaglandin release from the spleen. Nature New Biol 1971; 231: 237-9
4. Flower RJ. Drugs which inhibit prostaglandin biosynthesis. Pharmacol Rev 1974; 26: 33-67
5. Cronstein BN, Weissmann G. Target for anti-inflammatory drugs. Ann Rev Pharmacol Toxicol 1995; 35: 449-62
6. Flower RJ, Vane JR. Inhibition of prostaglandin synthase in brain explains the antipyretic activity of paracetamol (4-acetamidophenol). Nature New Biol 1972; 240: 410-1
7. Whittle BJR, Higgs GA, Eakins KE, et al. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature New Biol 1980; 284: 271-3
8. Vane JR. Prostaglandins and the aspirin-like drugs. Hosp Pract 1972; 7: 61-71
9. Lysz TW, Needleman P. Evidence for two distinct forms of fatty acid cyclooxygenase in brain. J Neurochem 1982; 38: 1111-7
10. Preston SJ, Arnold MH, Beller EM, et al. Comparative analgesic and anti-inflammatory properlies of sodium salicylate and acetylsalicyclic acid (aspirin) in rheumatoid arthritis. Br J Pharmacol 1989; 27: 607-11
11. Abramson SB, Weissmann G. The mechanism of action of non-steroidal anti-inflammatory drugs. Arthritis Rheum 1989; 32: 1-9
12. McCormack K. Non steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994; 59: 9-43
13. Fu JY, Masferrer JL, Seibert K, et al. The induction and suppression of prostaglandin H2 synthusc (cyclooxygenase) in human monocytes. J Biol Chem 1990; 265: 16737-40
14. Masferrer JL, Zweifel BS, Seibert K, et al. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990; 86: 1375-9
15. Raz A, Wyche A, Needlman P. Temporal and pharmacological division of fibroblast cyclooxygenase expression into transcriptional and translational phase. Proc Natl Acad Sci USA 1989; 86: 1657-61
16. Ristimäki A, Garfinkel S, Wessendorf J, et al. Induction of cyclooxygenase-2 by interleukin-1α. J Biol Chem 1994; 269: 11769-75
17. DuBois RN, Tsujii M, Bishop P, et al. Cloning and characterization of growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am J Physiol 1994; 266: G822-7
18. Sirois J, Richards JS. Transcriptional regulation of the rat proslaglandin endoperoxide synthase 2 gene in granulosa cells. J Biol Chem 1993; 268: 21931-8
19. Kujubu DA, Roddy ST, Fletcher BS, et al. Expression of the protein product of prostaglandin synthase-2/TIS10 gene in mitogen-slimulated swiss 3T3 cells. J Biol Chem 1991; 268: 5425-30
20. Xie W, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-6
21. O'Bannion MK, Sadowski HB, Winn V, et al. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991; 266: 23261-7
22. DeWitt DL, Meade E, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal anti-inflammatory drugs. Am J Med 1993; 95: 40S-4S
23. Vane JR. Towards a better aspirin. Nature New Biol 1994; 367: 215-6
24. Battistini B, Botting R, Bakhle YS. COX-1 and COX-2: Toward the development of more selective NSAIDs. Drug News Perpect 1994; 7: 501-11
25. Smith WL, Marnett LJ. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim Biophys Acta 1991; 1083: 1-17
26. Smith WL, DeWitt DL. Prostaglandin endoperoxide H synthases-1 and -2. Adv Immunol 1996; 62: 167-215
27. Kulmacz R J, Pendleton RB, Lands WEM. Interaction between peroxidase and cyclooxygenase activities in prostaglandin-endoperoxide synthase. Biochemistry 1994; 33: 5428-39
28. Xie W, Robertson DL, Simmons DL. Mitogen-inducible prostaglandin G/H synthase: a new target for nonsteroidal anti-inflammatory drugs. Drug Dev Res 1992; 25: 249-65
29. Percival MD, Ouellet M, Vincent CJ, et al. Purification and characterization of recombinant human cyclooxygenase-2. Arch Biochem Biophys 1994; 315: 111-8
30. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzyme by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268: 6610-4
31. Goppelt-Struebe M. Regulation of prostaglandin endoperoxide synthase (cyclooxygenase) isozyme expression. Prostaglandins Leukol Essent Fatty Acids 1995; 52: 213-22
32. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 125-40
33. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms? Am J Physiol 1996; 270: G393-400
34. Appleby SB, Ristimaki A, Neilson K, et al. Structure of the human cyclo-oxygenase-2 gene. Biochem J 1994; 302: 723-7
35. Kosaka T, Miyata A, Ihara H, et al. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem 1994; 221: 889-97
36. Lyons-Giordano B, Pratta MA, Galbraith W, et al. Interleukin-1 differentially modulates chondrocyte expression of cyclooxygenase-2 and phospholipase A2. Exp Cell Res 1993; 206: 58-62
37. Srivastava KS, Tetsuka T, Daphna-Iken D, et al. IL-1β stabilizes COX II mRNA in renal mesangial cells: role of 3′-untranslated region. Am J Physiol 1994; 267: F504-8
38. DeWitt DL, Meade E. Serum and glucocorticoid regulation of gene transcription and expression of the prostaglandin H synthase-1 and prostaglandin H synthase-2 isozymes. Arch Biochem Biophys 1993; 306: 94-102
39. Ristimäki A, Narko K, Hla T. Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J 1996; 318: 325-31
40. Hoff T, DeWitt DL, Kaever V, et al. Differentiation-associated expression of prostaglandin G/H synthase in monocytic cells. FEBS Lett 1993; 320: 38-42
41. Xie W, Fletcher BS, Andersen RD, et al. v-src induction of the TIS 10/PGS2 prostaglandin synthase gene is mediated by an ATF/CRE transcription response element. Mol Cell Biol 1994; 14: 6531-9
42. Inoue H, Nanayama T, Hara S, et al. The cyclic AMP response element plays an essential role in the expression of the human prostaglandin-endoperoxide synthase-2 gene in differentiated U937 monocytic cells. FEBS Lett 1994; 350: 51-4
43. Coleman RA, Smith WL, Narumiya S. Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994; 46: 205-29
44. Xie W, Merrill JR, Bradshaw WS, et al. Structural determination and promoter analysis of the chicken mitogen-inducible proslaglandin G/H synthase gene and genetic mapping of the murine homologue. Arch Biochem Biophys 1993; 300: 247-52
45. Scheinman RI, Cogswell PC, Lofquist AK, et al. Role of transcriptional activation of IkBα in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-6
46. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kB activity through induction of IkB synthesis. Science 1995; 270: 286-9
47. Feng L, Sun W, Xia Y, et al. Cloning two isoforms of rat cyclooxygenase: differential regulation of their expression. Arch Biochem Biophys 1993; 307: 169-77
48. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156-60
49. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12013-7
50. Yamagata K, Anderasson KI, Kaufmann WE, et al. Expression of a mitogen-inducible cyclooxygenase in brain neuron: regulation by synaptic activity and glucocorticoids. Neuron 1993; 11: 371-86
51. Iseki S. Immunocytochemical localization of cyclooxygenase-1 and -2 in the rat stomach. Histochem J 1995; 27: 323-8
52. Breder CD, Saper CB. Expression of inducible cyclooxygenase mRNA in the mouse brain after systemic administration of bacterial lipopolysaccharide. Brain Res 1996; 713: 64-9
53. Breder CD, DeWitt DL, Kraig RP. Characterization of inducible cyclooxygenase in the rat brain. J Comp Neurol 1995; 355: 296-315
54. Seibert K, Masferrer JL, Zhang Y, et al. Mediation of inflammation by cyclooxygenase-2. Agents Actions 1995; 46 Suppl.: 41-50
55. Smith WL, Wilkin GP. Immunochemistry of prostaglandin endoperoxide forming cyclooxygenases: the detection of cyclooxygenases in rat, rabbit, and guinea pig kidneys by immunofluorescence. Prostaglandins 1977; 13: 873-92
56. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994; 94: 2504-10
57. Morita I, Schinder M, Regier MK, et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 1995; 270: 10902-8
58. Yu K, Bayowa Y, Kallen CB, et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995; 270: 23975-83
59. Kliewer SA, Lenhard JM, Willson TM, et al. A prostaglandin J2 metabolite binds peroxisome proliferator-actived receptor γ and promotes adipocyte differentiation. Cell 1995; 83: 813-9
60. Murakami M, Matsumoto R, Austen KF, et al. Prostaglandin endoperoxide synthase-1 and -2 couple to different transmembrane stimuli to generate prostaglandin D2 in mouse bone marrow-derived mast cells. J Biol Chem 1994; 269: 22269-75
61. Kawata R, Reddy ST, Wolner B, et al. Prostaglandin synthase 1 and prostaglandin synthase 2 both participate in activation-induced prostaglandin D2 production in mast cell. J Immunol 1995; 155: 818-25
62. Karim S, Habib A, Levy-Toledano S, et al. Cyclooxygenases-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem 1996; 271: 12042-8
63. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83: 483-92
64. Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83: 473-82
65. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995; 378: 406-9
66. Picot D, Loll PJ, Garavito M. The x-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994; 367: 243-9
67. Blake C. Prostaglandin synthase: at the heart of the matter. Curr Biol 1994; 4: 452-4
68. DeWitt DL, El-Harith EA, Kraemer SA, et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxydes synthases. J Biol Chem 1990; 265: 5192-8
69. Tsai AL, Kulmacz RJ, Palmer G. Spectroscopic evidence for reaction of prostaglandin H synthase-1 tyrosyl radical with arachidonic acid. J Biol Chem 1995; 270: 10503-8
70. Loll PJ, Picot D, Garavito M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nature Struct Biol 1995; 2: 637-43
71. Kulmacz RJ. Topography of prostaglandin H synthase. J Biol Chem 1989; 264: 14136-44
72. Loll PJ, Picot D, Ekabo O, et al. Synthesis and use of iodinated nonsteroidal anti-inflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Biochemistry 1996; 35: 7330-40
73. Mancini JA, Riendeau D, Falgueyret JP, et al. Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. J Biol Chem 1995; 270: 29372-7
74. Bhattacharyya DK, Lecomte M, Ricke CJ, et al. Involvement of Arginine 120. Glutamate 524, and Tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1. J Biol Chem 1996; 271: 2179-84
75. Brooks PM, Day RO. Nonsteroidal anti-inflammatory drugs - differences and similarities. N Engl J Med 1991; 324: 1716-25
76. Luong C, Miller A, Barnett J, et al. Flexibility of the NSAID binding site in the structure of human cyclo-oxygenase-2. Nature Struct Biol 1996; 3: 927-33
77. Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of non steroidal anti-inflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993; 90: 11693-7
78. Laneuville O, Breuer DK, DeWitt DL, et al. Differential inhibition of human prostaglandin endoperoxide H synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994; 271: 927-34
79. Lecomte M, Laneuville O, Chuan J, et al. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 1994; 269: 13207-15
80. Mancini JA, O'Neill GP, Bayly C, et al. Mutation of serine 516 in human prostaglandin G/H synthase-2 to methionine or aspirin acetylation of this residue stimulates 15-R-HETE synthesis. FEBS Lett 1994; 342: 33-7
81. Allen KN. Aspirin - now we can see it. Nature Med 1995; 1: 882-3
82. Wennogle LP, Liang H, Quintavalla JC, et al. Comparison of recombinant cyclooxygenase-2 to native isoforms: aspirin labeling of the active site. FEBS Lett 1995; 371: 315-20
83. Garavito RM, Picot D, Loll PL. The x-ray structures of complexes of cyclooxygenase-1 and inhibitors. Med Chem Res 1995; 5: 375-83
84. Gierse JK, McDonald JJ, Hauser SD, et al. A single aminoacid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem 1996; 271: 15810-4
85. Rome LH, Lands WEM. Structural requirements for time-dependent inhibition of prostanglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci USA 1975; 72: 4863-5
86. Kulmacz RJ, Lands WEM. Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. J Biol Chem 1985; 260: 12572-8
87. Copeland RA, Williams JM, Giannaras J, et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci USA 1994; 91: 11202-6
88. Quellet M, Percival MD. Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J 1995; 306: 247-51
89. DeWitt DL, Bhattacharyya D, Lecomte M, et al. The differential susceptibility of prostaglandin endoperoxyde H synthase-1 and -2 to nonsteroidal anti-inflammatory drugs: aspirin derivatives as selective inhibitors. Med Chem Res 1995; 5: 325-43
90. Vago T, Bevilacqua M, Norbiato G. Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase / cyclooxygenase activity. Arzneimittel Forschung 1995; 45: 1096-8
91. Bhattacharyya DK, Lecomte M, Dunn J, et al. Selective inhibition of prostaglandin endoperoxide synthase-1 (cyclooxygenase-1) by valerylsalicylic acid. Arch Biochem Biophys 1995; 317: 19-24
92. Futaki N, Takahashi S, Yokoyama M, et al. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase / cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994; 47: 55-9
93. Barnett J, Chow J, Ives D, et al. Purification, characterization and selective inhibition of human prostaglandin G/H Synthase 1 and 2 expressed in the baculovirus system. Biochim Biophys Acta 1994; 1209: 130-9
94. O'Neill GP, Mancini JA, Kargman S, et al. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccina virus. Inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol 1994; 45: 245-54
95. Glaser K, Sung M-L, O'Neill K, et al. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur J Pharmacol 1995; 281: 107-11
96. Gierse JK, Hauser SD, Creely DP, et al. Expression and selective inhibition of the constitutive and inducible of human cyclooxygenase. Biochem J 1995; 305: 479-84
97. Engelhardt G, Bögel R, Schnitzler C, et al. Meloxicam: influence on arachidonic acid metabolism: part 1. In vitro findings. Biochem Pharmacol 1996; 51: 21-8
98. Chan CC, Boyce S, Bribeau C, et al. Pharmacology of selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and non human primate stomach. J Pharmacol Exp Ther 1995; 274: 1531-7
99. Klein T, Nusing RM, Pfeilschifter J, et al. Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 1994; 48: 1605-10
100. Churchill L, Graham AG, Shih CK, et al. Selective inhibition of human cyclooxygenase-2 by meloxicum. Inflammopharmacology 1996; 4: 125-35
101. Brideau C, Kargman S, Liu S, et al. A human whole blood assay for clinical evaluation of biological efficacy of cyclooxygenase inhibitors. Inflamm Res 1996; 45: 68-74
102. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 271: 1705-12
103. Panara MR, Greco A, Santini G, et al. Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido - 6 - (2,4 - difluorothiophenyl) - 1 - indanone (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthase. Br J Pharmacol 1995; 116: 2429-34
104. 2 production. Inflamm Res 1996; 45: 246-53
105. Grossman CJ, Wiseman J, Lucas LS, et al. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and COX 2 inhibitors, Inflamm Res 1995; 44: 253-57
106. Hayllar J, Bjarnason I. NSAIDs, COX-2 inhibitors, and the gut. Lancet 1995; 346: 521-2
107. Vane JR. NSAIDs, COX-2 inhibitors, and the gut [letter]. Lancet 1995; 346: 521-2
108. Vane JR, Botting RM. Mechanisms of action of anti-inflammatory drugs. Scand J Rheumatol 1996; 25 Suppl 102: 9-21
109. Griswold DE, Adams JL. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationals for selective inhibition and progress to date. Med Res Rev 1996; 16: 181-206
110. Cipollone F, Ganci A, Panara, et al. Effects of nabumetone on prostanoid biosynthesis in humans. Clin Pharmacol Ther 1995; 58: 335-41
111. Tofanetti O, Casciarri I, Cipolla PV, et al. Effects of nimesulide on cyclo-oxygenase activity in rat gastric mucosa and inflammatory exudate. Med Sci Res 1989; 17: 745-6
112. Masferrer JL, Zweifel BS, Manning PT et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-32
113. Richardson C, Emery P. The clinical implications of inhibition of the inducible form of cyclo-oxygenase. Drug Saf 1996; 15: 249-60
114. Simon LS. Non steroidal antiinflammatory drugs and their effects. The importance of COX 'selectivity'. J Clin Rheumatol 1996; 2: 135-40
115. Aslanian R, Carrathers NI, Kaminski JJ. Cyclooxygenase-2: a novel target for therapeutic intervention. Expert Opin Invest Drugs 3: 1323-5, 1994
116. Jensen NP. NSAIDs revisited cyclooxygenase 2 (COX-2) inhibitors. Med Chem Res 1995; 5: 319-24
117. Futaki N, Yoshikawa K, Hamasaka Y, et al. NS-398, a novel nonsteroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993; 24: 105-10
118. Wiesenberg-Böttcher I, Schweizer A, Green JR, et al. The pharmacological profile of CGP-28238, a highly potent anti-inflammatory compound. Agents Actions 1989; 26: 240-2
119. Swingle KF, Moore GI, Grant TJ. 4-nitro-2-phenoxymethane-sulfonanilide (R-805): a chemically novel anti-inflammatory agent. Arch Int Pharmacodyn Ther 1976; 221: 131-9
120. Gans KR, Galbraith W, Roman RJ, et al. Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 1990; 254: 180-7
121. Wong S, Lee SJ, Frierson MR, et al. Antiarthritic profile of BF-389. A novel anti-inflammatory agent with low ulcerogenic liability. Agents Actions 1992; 37: 90-8
122. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44: 1-10
123. Prasit P, Black WC, Chan CC, et al. L745.337: a selective cyclooxygenase-2 inhibitor. Med Chem Res 1995; 5: 364-74
124. Tanaka K, Makino S, Shimotori T, et al. Pharmacological studies of the new anti-inflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one. 2nd communication: effect on the arachidonic acid cascades. Arzneimittel Forschung 1992; 42: 945-50
125. Reitz DB, Li JJ, Norton MB, et al. Selective cyclooxygenase inhibitors: novel 1,2-diarylcyclopentenes are potent and orally active COX-2 inhibitors. J Med Chem 1994; 37: 3878-81
126. Reitz DB, Li JJ, Norton MB, et al. Novel 1,2-diarylcyclopentenes are selective, potent, and orally active cyclooxygenase inhibitors. Med Chem Res 1995; 5: 351-63
127. Hubbard RC, Koepp RJ, Yu S, et al. SC-58635 (celecoxib), a novel COX-2 selective inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study [abstract]. Arthritis Rheum 1996; 39 Suppl. 9: S 226
128. Tanaka K, Kawasaki H, Kurata K, et al. T-614, a novel anti rheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol 1995; 67: 305-14
129. Anderson GD, Hauser SD, McGarity KL, et al. Selective inhibition of cyclooxygenase (COX-2) reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996; 97: 2672-9
130. Tavares IA, Bishai PM, Bennett A. Activity of nimesulide on constitutive and inducible cyclooxygenases. Arzneimittel Forschung 1995; 45 (II): 1093-5
131. Taniguchi Y, Ikesue A, Yokoyama K, et al. Selective inhibition by nimesulide, a novel non steroidal anti-inflammatory drug, with prostaglandin endoperoxide synthase-2 activity in vitro. Pharm Res 1995; 1: 173-5
132. Vojnovic I, Amirmansour C, Warner TD, et al. Nimesulide: selectivity for COX-2 over COX-1 [abstract P4]. William Harvey Research Conferences on improved non-steroid anti-inflammatory drugs; COX-2 enzyme inhibitors; 1995 Oct 10-11: London
133. Engelhardt G, Homma D, Schlegel K, et al. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995; 44: 423-33
134. Futaki N, Arai I, Hamasaka Y, et al. Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J Pharm Pharmacol 1993; 45: 753-5
135. Davis R, Brogden RN. Nimesulide: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48: 431-54
136. Kankaanranta H, Moilanen E, Vapaatalo H. Effects of non steroidal anti-inflammatory drugs on polymorphonuclear leukocytes functions in vitro: focus on fenamates. Arch Pharmacol 1994; 350: 685-91
137. Tanaka K, Shimotori T, Makino S, et al. Pharmacological studies of the new anti-inflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one. 1st communication: Anti-inflammatory, analgesic and other related properties. Arzneimittel Forschung 1992; 42: 935-44
138. Magni E. The effect of nimesulide on prostanoid formation. Drugs 1993; 46 Suppl. 1: 10-4
139. Pairet M, Engelhardt E. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fund Clin Pharmacol 1996; 10: 1-15
140. Frölich JC. Prostaglandin endoperoxide synthase isoenzymes: the clinical relevance of selective inhibition. Ann Rheum Dis 1995; 54: 942-3
141. Noble S, Balfour JA. Meloxicam. Drugs 1996; 51: 424-30
142. Furst DE. Are there differences among nonsteroidal anti-inflammatory drugs? Arthritis Rheum 1994; 37: 1-9
143. Lanza FL. Gastrointestinal toxicity of newer NSAIDs. Am J Gastroenterol 1993; 88: 1318-23
144. Lichtenstein DR, Syngal S, Wolfe M. Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract. Arthritis Rheum 1995; 38: 5-18
145. Roth SH. NSAID gastropathy. A new understanding. Arch Intern Med 1996; 156: 1623-8
146. Fries JF, Miller SR, Williams CA, et al. Toward an epidemiology of gastropathy associated with nonsteroidal anti-inflammatory drug use. Gastroenterology 1989; 96: 647-55
147. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989; 86: 449-58
148. Price AH, Fletcher M. Mechanisms of NSAID-induced gastroenteropathy. Drugs 1990; 40 Suppl. 5: 1-11
149. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787-96
150. Polisson R. Nonsteroidal anti-inflammatory drugs: practical and theoretical considerations in their selection. Am J Med 1996; 100 Suppl. 2A: 31S-6S
151. Lichtenberger LM, Graziani LA, Dial EJ, et al. Role of surface-active phospholipids in gastric cytoprotection. Science 1983; 219: 1327-9
152. Lichtenberger LM, Wang Z-M, Romero JJ, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associated with zwitterionic phospholipids: insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nature Med 1995; 1: 154-8
153. Somasundaram S, Hayllar H, Rafi S, et al. The biochemical basis of non-steroidal anti-inflammatory drug induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 1995; 30: 289-99
154. Mahmud T, Scott DL, Bjarnason I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann Rheum Dis 1996; 55: 211-3
155. Rainsford KD. Mechanisms of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1989; 24 Suppl. 163: 9-16
156. Scarpignato C. Nonsteroidal anti-inflammatory drugs: How do they damage gastroduodenal mucosa? Dig Dis 1995; 13 Suppl. 1: 9-39
157. Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol 1990; 259: G462-7
158. Wallace JL, McKnight W, Miyasaka M, et al. Role of endothelial adhesion molecules in NSAID-induced gastro-mucosal injury. Am J Physiol 1993; 265: G993-8
159. Santucci L, Fiorucci S, Giansanti M, et al. Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha. Gut 1994; 35: 909-15
160. Appleyard CB, McCafferty DM, Tigley AW, et al. Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am J Physiol 1996; 270: G42-8
161. Whittle BJR, Lopez-Belmonte J, Moncada S. Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol 1990; 99: 607-11
162. Tepperman BL, Whittle BJR. Endogenous nitric oxide and sensory neuropeptides interact in the modulation of rat gastric microcirculation. Br J Pharmacol 1992; 105: 171-5
163. Wallace JL, Cirino G. The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs. Trends Pharmacol Sci 1994; 15: 405-6
164. Corhett JA, Kwon G, Turk J, etal. IL-1β induces the cooexpression of both nitric oxide synthase and cyclooxygenase by islets of langerhans: activation of cyclooxygenase by nitric oxide. Biochemistry 1993; 32: 13767-70
165. Wu KK. Inducible cyclooxygenase and nitric oxide synthase. Adv Pharmacol 1995; 33: 179-207
166. Salvemini D, Misko TP, Masterrer JL, et al. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993; 90: 7240-4
167. Salvemini D, Seibert K, Masferrer JL, et al. Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest 1994; 93: 1940-7
168. Lee M, Feldman M. Nonessential role of leukotrienes as mediators of acute gastric mucosal injury induced by aspirin. Dig Dis Sci 1992; 37: 1282-7
169. Wallace JL, McCafferty DM, Carter L, et al. Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxalin: anti-inflammatory without gastropathy? Gastroenterology 1993; 105: 1630-6
170. Rainsford KD. The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by nonsteroidal anti-inflammatory drugs in mice. Agents Actions 1987; 21: 316-9
171. Vaananen PM, Keenan CM, Grisham MB, et al. A pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAIDs - gastropathy. Inflammation 1992; 16: 227-40
172. Schrier DJ, Baragi VM, Connor DT, et al. The pharmacologic effects of 5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1,3,4-thiadiazole-2(3H)-thione, choline salt (Cl-986), a novel inhibitor of arachidonic acid metabolism in models of inflammation, analgesia and gastric irritation. Prostaglandins 1994; 47: 17-30
173. Argentieri DC, Ritchie DM, Ferro MP, et al. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with a potent anti-inflammatory activity and a favorable gastrointestinal profile. J Pharmacol Exp Ther 1994; 271: 1399-1408
174. Rainsford KD, Tsang S, Hunt RH, et al. Effects of non-steroidal anti-inflammatory drugs on prostaglandin H synthase isoenzyme 2 (cyclo-oxygenase 2) production by porcine gastric mucosa in organ culture. Inflammopharmacology 1995; 3: 299-310
175. Skeith KJ, Wright M, Davis P. Differences in NSAID tolerability profiles: fact or fiction? Drug Saf 1994; 10: 183-95
176. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257-63
177. Laporte JR, Carne X, Vidai X, et al. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Lancet 1991; 337: 85-9
178. Savage RL, Moller PW, Ballantyne CL et al Variation in the risk of peptic ulcer complications with nonsteroidal anti-inflammatory drug therapy. Arthritis Rheum 1993; 36: 84-90
179. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105: 1078-88
180. Langman MJS, Weil J, Wainwright P, et al. Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8
181. Garcia-Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72
182. Kurata JH, Nagawa AN, Abbey DE, et al. A prospective study of risk for peptic ulcer disease in seventh day adventists. Gastroenterology 1992; 102: 902-9
183. Lanza LL, Walker AM, Bortnichak EA, et al. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. Arch Intern Med 1995; 155: 1371-7
184. Fries J. Toward an understanding of NSAID-related adverse events: the contribution of longitudinal data. Scand J Rheumatol 1996; 25 Suppl. 102: 3-8
185. Committee on Safety of Medicines. Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions - 2. BMJ 1986; 292: 1190-1
186. Bateman DN. NSAIDs: time to re-evaluate gut toxicity. Lancet 1994; 343: 1051-2
187. Henry D, Lim LY, Garcia-Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-6
188. Rainsford KD, Quadir M. Gastrointestinal damage and bleeding from non-steroidal anti-inflammatory drugs: I. Clinical and epidemiological aspects. Inflammopharmacology 1995; 3: 169-90
189. Brune K, Rainsford KD, Wagner K, et al. Inhibition by anti-inflammatory drugs of prostaglandin production in cultured macrophages. Arch Pharmacol 1981; 315: 269-76
190. Roth SH. Endoscopy-controlled study of the safely of nabumetone compared with naproxen in arthritis therapy. Am J Med 1987; 83: 25-30
191. Lanza F, Rack MF, Lynn M, et al. An endoscopic comparison ot the effects of etodolac, indomethacin, ibuprofen, naproxen. and placebo on the gastrointestinal mucosa. J Rheumatol 1987; 14: 338-41
192. Bianchi-Porro G, Caruso I, Petrillo M, et al. A double-blind gastroscopic evaluation of the effects of etodolac and naproxen on the gastrointestinal mucosa of rheumatic patients. J Intern Med 1991; 229: 5-8
193. Jenner PN. A 12-month postmarketing surveillance study of nabumetone: a preliminary report. Drugs 1990; 40 Suppl. 5: 80-6
194. Stroehmann I, Fedder M, Zeidler H. German drug monitoring studies with nabumetone. Drugs 1990; 40 Suppl. 5: 38-42
195. Wilkens RF. An overview of the long-term safety experience of nabumetone. Drugs 1990; 40 Suppl. 5: 34-7
196. Schattenkirchner M. An updated safety profile of etodolac in several thousand patients. Eur J Rheumatol Inflamm 1990; 10: 56-65
197. Dandona P, Jeremy JY. Nonsteroidal anti-inflammatory drug therapy and gastric side effects: does nabumetone provide a solution? Drugs 1990; 40 Suppl. 5: 16-24
198. Blower PR. The unique pharmacologic profile of nabumetone. J Rheumatol 1992; 19 Suppl. 36: 13-20
199. Marini U, Spotti D. Gastric tolerability of nimesulide: a double-blind comparison of 2 oral dosage regimens and placebo. Drugs 1993; 46 Suppl. 1: 249-52
200. Patoia L, Santucci L, Furno P, et al. A 4-week, double-blind, parrallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br J Rheumatol 1996; 35 Suppl. 1: 61-97
201. Cipollini F, Mecozzi V, Altilia F. Endoscopic assessment of the effects of nimesulide on the gastric mucosa: comparison with indomethacin. Curr Ther Res 1989; 45: 1042-8
202. Pochobradsky MG, Mele G, Beretta A. Post-marketing survey of nimesulide in the short-term treatment of osteoarthritis. Drugs Exp Clin Res 1991; 17: 197-204
203. Dreiser RL, Benvelli DC. Long-term tolerability profile of nimesulide in the treatment of osteoarthritis. Drugs 1993; 46 Suppl. 1: 270-4
204. Wojtulewski JA, Schattenkirchner M, Barcelo P, et al. A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheumatol 1996; 35 Suppl. 1: 22-8
205. Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. Br J Rheumatol 1996; 35 Suppl. 1: 39-43
206. Linden B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996; 35 Suppl. 1: 35-8
207. Distel M, Mueller C, Bluhmki E. Global analysis of gastrointestinal safety of a new NSAID, meloxicam. Inflammopharmacology 1996; 4: 71-8
208. Distel M, Mueller C, Bluhmki E, et al. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996; 35 Suppl. 1: 68-77
209. Barner A. Review of clinical trials and benefit/risk ratio of meloxicam. Scand J Rheumatol 1996; 25 Suppl. 102: 29-37
210. Benett A, Tavares IA. NSAIDs, COX-2 inhibitors, and the gut [letter]. Lancet 1995; 346: 1105
211. Eberhart CE, Coffey RJ, Radhika A, et al. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-8
212. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55: 3785-9
213. Kargman SL, O'Neill GP, Vickers PJ, et al. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 55: 2556-9
214. Tsujii M, DuBois R. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501
215. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-89
216. Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase 2 is expressed abnormally in human colocancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996; 93: 4816-20
217. Thun MJ, Namboodiri MM, Heath Jr CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-6
218. Thun MJ, Namboodiri MM, Call EE, et al. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-7
219. Giovannuci E, Rimm EB, Stampfer MJ, et al. Aspirin use and risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241-6
220. Peleg II, Hilda T, Brown SH, et al. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994; 154: 394-9
221. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer 1994; 74: 1847-54
222. Shiff SJ, Koutsos MI, Qiao L, et al. Nonsteroidal anti-inflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 1996; 22: 179-88
223. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109: 994-8
224. Marcus AJ. Aspirin as prophylaxis against colorectal cancer. N Engl J Med 1995; 333: 656-8
225. Planas AM, Soriano MA, Rodriguez-Farre E, et al. Induction of cyclooxygenase-2 mRNA and protein following transient focal ischemia in the rat brain. Neurosci Lett 1995; 200: 187-90
226. Chen J, Marsh T, Zhang JS, et al. Expression of cyclooxygenase 2 in rat brain following kainate treatment. Neuroreport 1995; 6: 245-8
227. Adams J, Collaço-Moraes Y, De Belleroche J. Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J Neurochem 1996; 66: 6-13
228. Spence P, Franco R, Wood A, et al. Mechanisms of apoptosis as drug targets in the central nervous system. Expert Opin Ther Patents 1996; 6: 345-66
229. Tocco G, Freire-Moar J, Aisen PS, et al. Inflammation and alzheimer's disease: the role of cyclooxygenase-2 (COX-2). In: William Harvey Research Conferences. New targets in inflammation: inhibitors of COX-2 or adhesion molecules [abstract P16]. New-Orleans, 1996; vol. 8: 37
230. Hampel H, Müller N. Inflammatory and immunological mechanisms in Alzheimer's disease. Drug News Perspect 1995; 8: 599-608
231. Cochran FR, Vitek MP. Neuroinflammatory mechanisms in Alzheimer's disease: new opportunities for drug discovery. Expert Opin Invest Drugs 1996; 5: 449-55
232. Fricker J. NSAIDs may reduce risk of Alzheimer's disease [editorial]. Lancet 1996; 347: 958
233. Norris SH. Renal eicosanoids. Semin Nephrol 1990; 10: 64-88
234. Toto RD. The role of prostaglandins in NSAID induced renal dysfunction. J Rheumatol 1991; 18 Suppl. 28: 22-5
235. Shield MJ. Anti-inflammatory drugs and their effects on cartilage synthesis and renal function. Eur J Rheumatol Inflamm 1993; 13: 7-16
236. Smith WL, Bell TG. Immunohistochemical localization of the prostaglandin-forming cyclooxygenase in the renal cortex. Am J Physiol 1978; 235: F451-7
237. Rzymkiewicz D, Leingang K, Baird N, et al. Regulation of prostaglandin endoperoxide synthase gene expression in rat mesangial cells by interleukin-1β. Am J Physiol 1994; 266: F39-45
238. Hughes AK, Padilla E, Kutchera WA, et al. Endothelin-1 induction of cyclooxygenase-2 expression in rat mesangial cells. Kidney Int 1995; 47: 53-61